Alpha DNA Investment Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
McDonald's
MCD
|
+$2.38M |
| 2 |
Walmart Inc
WMT
|
+$2.38M |
| 3 |
JPMorgan Chase
JPM
|
+$2.13M |
| 4 |
Fate Therapeutics
FATE
|
+$1.92M |
| 5 |
Fortinet
FTNT
|
+$1.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$2.05M |
| 2 |
Pfizer
PFE
|
+$1.44M |
| 3 |
CVS Health
CVS
|
+$1.41M |
| 4 |
MetLife
MET
|
+$1.4M |
| 5 |
Deere & Co
DE
|
+$1.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 18.71% |
| 2 | Technology | 15.05% |
| 3 | Industrials | 8.12% |
| 4 | Healthcare | 7.38% |
| 5 | Energy | 5.52% |
Similar funds
Alpha DNA Investment Management's Q4 2022 Portfolio in Review
As of Q4 2022, Alpha DNA Investment Management held 215 positions worth $283M, up 135% from $120M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Alpha DNA Investment Management deployed $72.6M of net new capital in Q4 2022, opening 70 new positions and adding to 65 existing holdings. Its largest new stake was Fate Therapeutics: 102,094 shares worth $1.03M.
By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 19% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was ExxonMobil, an estimated $2.05M trimmed.
- Alpha DNA Investment Management's largest Q4 2022 buy was Fate Therapeutics: 102,094 shares worth $1.03M.
- Alpha DNA Investment Management added most to McDonald's in Q4 2022, an estimated $2.38M increase.
- Alpha DNA Investment Management's biggest Q4 2022 reduction was ExxonMobil, cutting an estimated $2.05M.
- Alpha DNA Investment Management fully exited CVS Health in Q4 2022, selling an estimated $1.41M.
- Alpha DNA Investment Management's ten largest holdings make up 43% of its $283M portfolio in Q4 2022.
- Alpha DNA Investment Management opened 70 new positions and closed 66 in Q4 2022.
- Alpha DNA Investment Management's portfolio value rose 135% quarter-over-quarter to $283M.
Based on Alpha DNA Investment Management's 13F filing for Q4 2022, filed 27 Jan 2023.